Three Seasons Wealth LLC Invests $589,000 in Boston Scientific Corporation $BSX

Three Seasons Wealth LLC acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the third quarter, Holdings Channel reports. The fund acquired 6,031 shares of the medical equipment provider’s stock, valued at approximately $589,000.

Several other large investors have also recently added to or reduced their stakes in BSX. Steph & Co. bought a new stake in Boston Scientific in the third quarter valued at $25,000. 1248 Management LLC bought a new stake in Boston Scientific in the 1st quarter valued at about $26,000. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Sound Income Strategies LLC boosted its stake in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Finally, Kilter Group LLC bought a new position in Boston Scientific in the 2nd quarter worth about $30,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.1%

Shares of Boston Scientific stock opened at $96.02 on Monday. The business has a fifty day simple moving average of $98.53 and a 200-day simple moving average of $101.09. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The firm has a market cap of $142.35 billion, a price-to-earnings ratio of 51.35, a price-to-earnings-growth ratio of 1.93 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the previous year, the business earned $0.63 earnings per share. Boston Scientific’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 143,095 shares of company stock worth $14,228,950 in the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BSX. Royal Bank Of Canada boosted their price objective on Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Friday, November 21st. Needham & Company LLC reissued a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a report on Friday, October 17th. Cowen restated a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. Finally, Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their target price for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $124.85.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.